Open Access Open Badges Editorial

JTM’s Tumor immunology goes broad: announcing the Immunobiology and Immunotherapy section

Adrian Bot12*, Francesco Marincola345 and Pedro Romero67

Author Affiliations

1 Kite Pharma, Inc, 10924 Le Conte Avenue, Los Angeles, CA 90024, USA

2 Incoming Section Editor of Immunobiology and Immunotherapy of JTM, Bethesda, USA

3 Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center, Bethesda, MD, USA

4 Trans-NIH Center for Human Immunology, National Institutes of Health, Bethesda, MD, USA

5 Editor in Chief of JTM, Bethesda, USA

6 Ludwig Center for Cancer Research of the University of Lausanne, Avenue Pierre-Decker 4, Lausanne, 1011, Switzerland

7 Incoming Editor in Chief of the Journal for Immunotherapy of Cancer, the new BMC journal of the Society for Immunotherapy of Cancer (SITC), Lausanne, Switzerland

For all author emails, please log on.

Journal of Translational Medicine 2013, 11:2  doi:10.1186/1479-5876-11-2

Published: 4 January 2013


For the last four years the Journal of Translational Medicine (JTM) has hosted the Section of Tumor Immunology and Biological Cancer Therapy. Under the editorial leadership of Dr. Pedro Romero and with the direct support of the Society for Immunotherapy of Cancer (SITC), this section enriched the communication between basic immunological sciences and the clinical investigation arena in oncology. We are re-launching this Section of JTM, now entitled Immunobiology and Immunotherapy, succeeding Tumor Immunology and Biological Cancer Therapy. While aiming to build on the editorial success and focus of its predecessor, this novel Section will have a broader scope, hosting translational immunology topics pertaining to immunotherapy beyond oncology, including disciplines such as inflammation, autoimmunity, transplantation, metabolic disorders and others. As the vision of this re-launched Section of JTM broadens up to serve a communication need for translational immunologists involved with immunotherapy irrespectively of the therapeutic area, a novel and focused journal entitled Journal for Immunotherapy of Cancer (JITC) has just been initiated, sponsored by the SITC.